Aminoglycosides Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Aminoglycosides are bactericidal antibiotics that work by binding to the bacterial 30S ribosomal subunit, making them essential in treating severe infections where beta-lactam agents are insufficient. The market encompasses products such as neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, and kanamycin, available in injectable, topical, and oral formulations. North America and Europe account for the largest share of global revenue, supported by advanced hospital infrastructure and high antibiotic consumption.

• •Global market size estimated at USD 1.95 billion in 2025, with growth of roughly 4.1% per year.
• •Key products include gentamicin, amikacin, tobramycin, and neomycin, with gentamicin typically among the highest-volume molecules.
• •Hospital injectable formulations represent the dominant share of revenue within the product mix.

Rising rates of antimicrobial resistance among gram-negative pathogens, particularly Pseudomonas aeruginosa, Acinetobacter, and Enterobacteriaceae, are sustaining clinical reliance on aminoglycosides as a backbone of combination therapy. An expanding geriatric population vulnerable to pneumonia, sepsis, and complicated urinary tract infections is also lifting demand. In addition, broader access to generics, growing incidence of cystic fibrosis, and rising tuberculosis cases requiring streptomycin continue to underpin volume growth in emerging and developed markets.

• •Increasing prevalence of multi-drug resistant gram-negative infections is a primary growth catalyst.
• •Aging populations and higher rates of sepsis and hospital-acquired infections are expanding the addressable patient base.
• •Patent expiries and the resulting influx of low-cost generics are making aminoglycosides more widely accessible.

By product, gentamicin and amikacin lead the market due to their broad-spectrum activity and use in empiric therapy for sepsis, while tobramycin is widely used for cystic fibrosis-associated lung infections. Injectable formulations dominate by route of administration, with hospitals as the principal end user. Regionally, North America contributes the largest revenue share, followed by Europe, while Asia-Pacific is anticipated to record the fastest growth owing to rising healthcare spending, urbanization, and a growing burden of infectious disease.

• •Second and third generation aminoglycosides such as amikacin and isepamicin are gaining share over older first-generation agents.
• •North America and Europe together account for the majority of global revenue, while Asia-Pacific is the fastest-growing region.
• •Topical and otic formulations of neomycin and tobramycin represent smaller but stable consumer and veterinary segments.

What are the recent trends and outlook?

A central trend is the development of next-generation aminoglycosides engineered to evade common resistance mechanisms, alongside inhaled liposomal and dry-powder formulations of tobramycin for cystic fibrosis and non-CF bronchiectasis. Regulators and clinicians are also promoting antimicrobial stewardship, which is shifting some use away from older aminoglycosides toward newer agents in inpatient settings. Over the medium term, public and private investment in antibiotic pipelines, combined with revised reimbursement frameworks such as subscription-based models, is expected to support modest but stable expansion of the market.

• •Next-generation aminoglycosides and inhaled tobramycin formulations are key areas of clinical and commercial development.
• •Antimicrobial stewardship programs are influencing prescribing patterns in hospitals worldwide.
• •Global market value is expected to continue growing in the mid-single digits through the forecast horizon on the back of resistance-driven demand.